Clinical variable | Sorafenib, n (%) | Sunitinib, n (%) | P | |
---|---|---|---|---|
Age (years) | <65 | 373 (77.2) | 309 (85.4) | 0.004 |
≥65 | 110 (22.8) | 53 (14.6) |  | |
Gender | Male | 353 (73.1) | 276 (76.2) | 0.302 |
Female | 130 (26.9) | 86 (23.8) | Â | |
Pathology | Clear cell type | 408 (84.5) | 331 (91.4) | 0.002 |
Non-clear cell type | 75 (15.5) | 31 (8.6) | Â | |
ECOG | 0 | 230 (47.6) | 238 (65.7) | <0.001 |
1 | 188 (38.9) | 94 (26.0) | Â | |
2 | 58 (12.0) | 29 (8.0) | Â | |
3 | 7 (1.4) | 1 (0.3) | Â | |
Previous nephrectomy | Yes | 376 (77.8) | 298 (82.3) | 0.120 |
No | 107 (22.2) | 64 (17.7) | Â | |
MSKCC | Low risk | 173 (35.8) | 151 (41.7) | <0.001 |
Moderate risk | 237 (49.1) | 192 (53.0) | Â | |
High risk | 73 (15.1) | 19 (5.2) | Â | |
Heng’s criteria | Low risk | 183 (37.9) | 144 (39.8) | 0.016 |
Moderate risk | 227 (47.0) | 187 (51.7) | Â | |
High risk | 73 (15.1) | 31 (8.6) | Â | |
Number of metastatic organs | 1 | 207 (42.9) | 174 (48.1) | 0.129 |
2 | 182 (37.7) | 109 (30.1) | Â | |
3 | 75 (15.5) | 66 (18.2) | Â | |
4 | 19 (3.9) | 13 (3.6) | Â | |
Lung metastasis | No | 174 (36.0) | 106 (29.3) | 0.046 |
Yes | 309 (64.0) | 256 (70.7) | Â | |
Simple lung metastasis | No | 380 (78.7) | 251 (69.3) | 0.002 |
Yes | 103 (21.3) | 111 (30.7) | Â | |
Bone metastasis | No | 319 (66.0) | 254 (70.2) | 0.207 |
Yes | 164 (34.0) | 108 (29.8) | Â | |
Simple bone metastasis | No | 445 (92.1) | 341 (94.2) | 0.276 |
Yes | 38 (7.9) | 21 (5.8) | Â | |
Liver metastasis | No | 421 (87.2) | 335 (92.5) | 0.013 |
Yes | 62 (12.8) | 27 (7.5) | Â | |
Lymph node metastasis | No | 323 (66.9) | 248 (68.5) | 0.656 |
Yes | 260 (33.1) | 114 (31.5) | Â | |
RECIST response | CR | 5 (1.0) | 4 (1.1) | Â |
PR | 77 (15.9) | 72 (19.9) | Â | |
SD | 346 (71.6) | 244 (67.4) | Â | |
PD | 55 (11.4) | 42 (11.6) | 0.110 | |
Second line treatment | Yes | 132 (27.3) | 81 (22.4) | Â |
No | 351 (72.7) | 281 (77.6) | Â |